Evidence map›Paper›PMID 36143241›Full record

ArticleJournal of personalized medicine2022

Personalized Approach in Treatment of Neovascular Age-Related Macular Degeneration.

Radina Kirkova, Snezhana Murgova, Vidin Kirkov, Ivan Tanev

Open access · goldAbstract read
In one paragraph

Article in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. The Challenges and Therapeutic Prospects in Eye Disease.Journal of personalized medicine · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Radina KirkovaDepartment of Ophthalmology, ENT and Maxillofacial Surgery, Medical University-Pleven, 5800 Pleven, Bulgaria.ORCID 0000-0002-1712-9877
Snezhana MurgovaDepartment of Ophthalmology, ENT and Maxillofacial Surgery, Medical University-Pleven, 5800 Pleven, Bulgaria.ORCID 0000-0002-7413-8614
Vidin KirkovDepartment of Health Policy and Management, Faculty of Public Health "Prof. Dr. Tzekomir Vodenicharov", Medical University of Sofia, 1000 Sofia, Bulgaria.
Ivan TanevEye Clinic "Zrenie", 1000 Sofia, Bulgaria.
IRCCS Humanitas Research Hospital · ITMedical University of Sofia · BGUniversity Hospital Dr. Georgi Stranski · BG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAge-related macular degeneration (AMD) is a progressive, degenerative disease of the central retina. AMD is subdivided into "dry" (atrophic), "wet" (exudative), and neovascular (nAMD) forms. In recent years, the concepts about nAMD changed with the development of optical coherence tomography-angiography (OCT-A) and intravitreal anti-VEGF treatment. The aim of this study was to define the morphologic type of the neovascular membrane (NVM) before treatment with OCT-A and to register vascular remodeling after treatment with anti-VEGF. We also analyzed the relationship between NVM and visual acuity.

methodsThe study was retrospective and included 119 patients with newly diagnosed, treatment-naïve nAMD. All the patients underwent full ophthalmic examination and also fluoresceine angiography and optical coherence tomography-angiography (OCT-A).

resultsBased on the collected data, we found repetitive regularities.

conclusionThe analysis of our results could be used as prognostic markers for the evolution of the disease and as a basis for new treatment strategies, depending on the naïve NVM morphologic type.

Indexed as

AMDanti-VEGFapproachneovascularizationOCT-Apersonalizedvascular remodeling

Identifiers

PMID36143241
PMCPMC9501367
OpenAlexW4295067581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.